Anti-ERBB2 Therapeutic Antibody (Margetuximab) (CAT#: TAB-761)

Recombinant chimeric (mouse/human) antibody expressed in CHO binding to human ERBB2. Margetuximab is a monoclonal antibody designed for the treatment of cancer.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Tested Data
  • Datasheet
  • MSDS
  • COA
SPR

Figure 1 Anti-ERBB2 Recombinant Antibody (Margetuximab) (TAB-761) in SPR

SPR assays of TAB-761.
The affinity of Anti-ERBB2 Therapeutic Antibody (Margetuximab) (TAB-761) was determined by SPR.
Captured TAB-761 on CM5 Chip via Anti-Human IgG (Fc) can bind Human ERBB2 protein with an affinity constant of 1.21 nM as determined in a SPR assay (Biacore 8K).


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Chimeric (Human/Mouse)
  • Type
  • IgG1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
  • CAS
  • 1350624-75-7
  • Generic Name
  • margetuximab
  • MW
  • 145.9 kDa
  • Related Disease
  • Solid tumors

Target

  • Alternative Names
  • margetuximab;1350624-75-7;MGAH22;4D5;ERBB2;v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian);NGL, v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived onco

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Margetuximab.

See other products for "Margetuximab"

Afuco™ Anti-ERBB2 ADCC Therapeutic Antibody (Margetuximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (mouse/human) antibody expressed in CHO binding to human ERBB2. Margetuximab is a monoclonal antibody designed for the treatment of cancer.

See other products for "ERBB2"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2021 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart